Investigational Drug Information for Rintatolimod
✉ Email this page to a colleague
What is the drug development status for Rintatolimod?
Rintatolimod is an investigational drug.
There have been 20 clinical trials for Rintatolimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are AIM ImmunoTech Inc., Roswell Park Cancer Institute, and National Cancer Institute (NCI).
There is one US patent protecting this investigational drug and sixteen international patents.
Summary for Rintatolimod
| US Patents | 1,124 |
| International Patents | 16,080 |
| US Patent Applications | 4,647 |
| WIPO Patent Applications | 1,443 |
| Japanese Patent Applications | 807 |
| Clinical Trial Progress | Phase 2 (2021-11-30) |
| Vendors | 7 |
Recent Clinical Trials for Rintatolimod
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Amarex Clinical Research | Phase 2 |
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | AIM ImmunoTech Inc. | Phase 2 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | Roswell Park Cancer Institute | Phase 1/Phase 2 |
Clinical Trial Summary for Rintatolimod
Top disease conditions for Rintatolimod
Top clinical trial sponsors for Rintatolimod
US Patents for Rintatolimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Rintatolimod | ⤷ Try a Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Try a Trial |
| Rintatolimod | ⤷ Try a Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try a Trial |
| Rintatolimod | ⤷ Try a Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| Rintatolimod | ⤷ Try a Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rintatolimod
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Rintatolimod | Australia | AU2010313103 | 2029-11-02 | ⤷ Try a Trial |
| Rintatolimod | Australia | AU2012249360 | 2029-11-02 | ⤷ Try a Trial |
| Rintatolimod | Australia | AU2013203097 | 2029-11-02 | ⤷ Try a Trial |
| Rintatolimod | Australia | AU2016201790 | 2029-11-02 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
